Conference Call is November 8 at 4:30 p.m. ET/1:30 p.m. P RICHLAND, WASHINGTON – October 24, 2018 – IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today...
Dr. John Sheldon brought his experience with brachytherapy to bear with a targeted treatment for Barbie after her cervical cancer returned in 2015.
Radiation Oncologist Dr. John Sylvester, MD shared a few minutes with us at ABS 2018 discussing recent advancements in prostate brachytherapy and their implications for prostate cancer patients.
Dr. Sylvester discusses how the development of new technology can bring new treatment modalities that are frequently pressed upon patients in spite of brachytherapy’s efficacy and rapid side effect resolution.
Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top...
Capitalizing on the same value ASTRO provides for radiation oncologists to connect with peers in a concentrated way, we invite the entire community to visit the Isoray team at ASTRO 2018.
In a new study, radiation oncologists find that DR-BT is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer.
Year over year fourth quarter revenues increased 17% Sixth Consecutive Quarter of Year-Over-Year Revenue Increases Full year revenues increased 24% RICHLAND, Wash., September 25, 2018 -- IsoRay (NYSE AMERICAN: ISR), a medical technology company and innovator in seed...
According to Dr. Sylvester, brachytherapy provides many advantages over surgery for prostate cancer treatment. This underscores the importance of prostate cancer patients becoming aware of brachytherapy as a treatment option.
The past 12 to 18 months have seen remarkable new scientific evidence come to light regarding the attributes and benefits of brachytherapy, including Cesium-131, for prostate cancer treatment.
Richland, Wash., Sept. 10, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to...
As the importance of patient involvement in determining their optimal post-treatment quality of life, these organizations educate and support the men and families affected by prostate cancer.